Purespring Therapeutics raises £80/$105 million in a Series B …

London – 9 October 2024 – Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

CouponFollow Extension

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 – Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

purespringtx.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

yahoo.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

globenewswire.com

$105
OFF

Purespring Bottles Up $105M Series B For Kidney Gene Therapy

6 days from now

Oct 9, 2024 · London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series …

fiercebiotech.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Oct 9, 2024 · Funds raised will support Purespring in advancing its AAV pipeline of gene therapy programmes to treat kidney disease, including its lead programme targeting IgA Nephropathy …

businessupturn.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Oct 9, 2024 · Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 million …

icheme.org

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

yahoo.com

$105
OFF

Purespring Therapeutics Secures £80/$105M In Series B Funding …

6 days from now

Oct 9, 2024 · Purespring Therapeutics, a pioneering gene therapy company specializing in transforming the treatment of kidney diseases, has recently secured £80/$105 million in a …

ainvest.com

£80
OFF

Purespring Therapeutics Series B Financing – Company …

6 days from now

9 October 2024 Syncona Limited Purespring Therapeutics raises £80 million in a Series B financing · Purespring raises £80 million in a Series B financing, with Syncona committing …

ft.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Purespring Therapeutics, said: “Syncona founded Purespring with the vision of creating the world’s leading kidney gene therapy company, and we have been impressed with its progress. …

purespringtx.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

London – 9 October 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised …

biospace.com

$105
OFF

Purespring Therapeutics Raises $105M In Series B Financing

6 days from now

Oct 9, 2024 · Purespring Therapeutics, a London, UK-based gene therapy company focused on enhancing the treatment of kidney diseases, raised $105M in Series B funding.. The round …

finsmes.com

£80
OFF

Purespring Therapeutics Secures £80 Million In Series B Funding

6 days from now

Oct 9, 2024 · Syncona’s £19.9m commitment includes the final £9.9 million tranche of its Series A commitment and an additional £10m. Syncona’s interest in Purespring is now valued at £51.2 …

pharmatimes.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In Series B …

6 days from now

London, 7 October, 2024 - Purespring Therapeutics, a pioneering gene therapy company focused on transforming the treatment of kidney diseases, today announces it has raised £80/$105 …

forbion.com

$105
OFF

Purespring Therapeutics Raises £80/$105 Million In A Series B …

6 days from now

Oct 9, 2024 · Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases. Oversubscribed financing led by Sofinnova Partners in …

businessinsider.com

£80
OFF

Purespring Therapeutics Raises £80 Million In A Series B Financing

6 days from now

Oct 10, 2024 · Purespring raises £80 million in a Series B financing, with Syncona committing £19.9 million as part of a leading syndicate of life science investors; Proceeds will be used to …

pharmiweb.com

FAQs about Purespring Therapeutics raises £80/$105 million in a Series B … Coupon?

Does purespring therapeutics have a series B financing?

Purespring Therapeutics raises £80/$105 million in a Series B financing to transform the treatment of kidney diseases Oversubscribed financing led by Sofinnova Partners in collaboration with Gilde Healthcare, Forbion, British Patient Capital and founding investor Syncona ...

Who is purespring Therapeutics?

Maina Bhaman, Partner at Sofinnova Partners, added: Purespring Therapeutics is pioneering the treatment of kidney disease. The team’s ambition and calibre epitomise Sofinnova’s mission of scientific and entrepreneurial excellence in delivering transformative treatments to patients. ...

Will purespring bring kidney-tweaking gene therapy to the clinic?

London-based biotech Purespring Therapeutics plans to bring their kidney-tweaking gene therapy to the clinic with the help of a new £80 million (about $105 million) pool of series B cash. ...

What is purespring & how does it work?

Purespring’s platform technology allows working copies of genes to be delivered with high efficiency and specificity to podocytes, opening up a new and highly differentiated modality for disease modifying treatments of a broad range of kidney diseases. ...

How does purespring treat kidney disease?

Purespring is the first company to successfully treat kidney disease models by directly targeting the podocyte, a specialised cell implicated in approximately 60% of renal diseases, through its proprietary adeno-associated viral (AAV) gene therapy platform. The Company currently has a pipeline of programmes in development. ...

What will ps-002 funding mean for purespring?

The funds raised will allow us to bring our novel treatments to patients in the clinic.” The funds will filter to drugs throughout Purespring’s pipeline, including lead asset PS-002, which is being developed for IgA nephropathy, a disease caused by a build-up of immunoglobulin A in the kidneys. ...